US Tech Wake-Up: The Stories That Moved the Market This Morning

Etched just raised three hundred million dollars at a valuation north of ten billion. That's for a Series C. And it's the highest valuation Sequoia has ever led for a round at that stage. In our last briefing, we talked about Meta and Microsoft cutting thousands of jobs, but it's clear the AI funding frenzy isn't just continuing—it’s hitting a new gear. And it's not the only place big money is moving. Today, July twenty-fourth, two different longevity-focused biotech companies are hitting the public markets. Scribe Therapeutics, a CRISPR company, priced its IPO at fifteen dollars a share and starts trading today on Nasdaq under the ticker SCTX. At the same time, Instinct Bio, a regenerative medicine platform out of Tokyo, also just debuted on the Nasdaq.

Then you have the insurance startup Corgi. It just closed another funding round that doubled its valuation to FOUR billion dollars... in the last eight weeks. Even by today's standards, that is an incredible pace. On the other end of the market, EV maker Faraday Future just executed a one-for-one-hundred-fifty reverse stock split this morning, basically a move to keep its stock from getting delisted. And in a quieter, but still significant development, Syntec Optics officially joined the Russell 3000 index, cementing its place among key US public companies for its work in defense and space tech. Okay, so there's a lot happening. But let's go back to those first two themes, because they show you where the REAL money is concentrating right now. AI hardware and human longevity.

First, Etched. What are they even building that's worth over ten billion dollars before they're a household name? They make something called "frontier inference hardware." So, you know how companies like Nvidia build these massive, power-hungry GPUs to TRAIN AI models? That's one half of the equation. But once the model is trained, you have to actually RUN it. That's called inference. Every single time you ask a chatbot a question or generate an image, that's an inference task. Etched is betting that as these AI models become astronomically complex, they'll need specialized chips just to run them efficiently. They're building a custom chip—an ASIC—designed to do one thing and one thing only: run a specific type of advanced AI model called a Transformer.

It's a huge gamble. If that model architecture changes in the future, their chip could become a very expensive paperweight. But if they're right... they've just built the engine for the next generation of artificial intelligence. And Sequoia putting in a record-breaking valuation tells you they think Etched is VERY right. Now, the second huge bet we're seeing play out today is on rewriting human biology. It is not a coincidence that two longevity biotechs, Scribe and Instinct, went public on the exact same day. This is a signal. The market is starting to treat "extending healthy lifespan" as a serious, investable category—not just science fiction. Scribe Therapeutics is a CRISPR company. But here’s the key difference. They're focused on in vivo gene editing.

That means editing genes directly INSIDE the body. No taking cells out, editing them in a lab, and putting them back in. Their goal is to create durable therapies... maybe even prevent diseases before they can ever start. Think of it as patching the source code of your DNA before the program can crash. Then you have Instinct Bio. They're coming at it from a different angle—regenerative medicine. This is about using the body's own systems to repair and regenerate tissues. They're already generating revenue, which is rare for a biotech at this stage. Having both of these companies hit the Nasdaq on the same morning shows you the capital markets are officially open for business for companies whose primary product is... more time. So when you pull back, what did we actually see today?

It's a massive divergence. While some parts of the tech world are contracting, with buyouts and reverse stock splits, the venture capital isn't drying up. It's concentrating. It’s making enormous, almost philosophical bets. The money is flowing into two areas: the hardware to power artificial intelligence, and the biology to extend our own. The market isn't just looking for the next app. It's funding the companies that are trying to rewrite the rules of code, and the companies trying to rewrite the code in our own cells.